Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Assets (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Non-Current Assets data on record, last reported at $5.2 million in Q3 2025.

  • For Q3 2025, Non-Current Assets rose 15.01% year-over-year to $5.2 million; the TTM value through Sep 2025 reached $17.3 million, up 1.79%, while the annual FY2024 figure was $3.9 million, 0.1% changed from the prior year.
  • Non-Current Assets reached $5.2 million in Q3 2025 per VRDN's latest filing, up from $3.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $5.2 million in Q3 2025 and bottomed at $1.3 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $3.8 million, with a median of $3.8 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: surged 279.21% in 2021, then decreased 11.81% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $3.5 million in 2021, then increased by 10.49% to $3.9 million in 2022, then grew by 0.71% to $3.9 million in 2023, then fell by 0.1% to $3.9 million in 2024, then soared by 32.55% to $5.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $5.2 million in Q3 2025, $3.9 million in Q4 2024, and $4.5 million in Q3 2024.